KOELIS’ Post

Prostate cancer is the second leading cause of cancer death in men. Windsong was the first in the region to offer Multiparametric Prostate MRI, an analytical and interventional imaging option that can help pinpoint areas of concern in the prostate. Prostate MRI help urologists and oncologists screen for prostate cancer more effectively, allowing them to visualize suspected cancer better and often eliminating the need for an ultrasound biopsy and associated side effects. https://lnkd.in/eQ7EcJFZ

Great multidisciplinary session on invasive lobular cancer yesterday at the annual meeting of ESMO - European Society for Medical Oncology. Bottom line for the imaging part: -       Local staging: contrast-enhanced breast imaging (breast MRI / CEM) should be performed in the case of ILC -       Distant staging: be aware of potential hypometabolic ILC on 18F-FDG PET, with consequently decreased sensitivity to detect distant metastases. Potential novel PET tracers might help in near future. Prof. Jens Huober, Prof. Ava Kwong, Prof. Giuseppe Floris

*Radiology paper* Gyne can also participate Effectiveness of Contrast-Enhanced Mammography in Breast Cancer Screening: A Randomized Controlled Trial" Available positions 1-8 1- booked 2- 40000 3- 35000 4- 30000 5- 25000 6-22000 7- 20000 8- 15000 Journal is Hec W category,

*Radiology paper* Effectiveness of Contrast-Enhanced Mammography in Breast Cancer Screening: A Randomized Controlled Trial" Available positions 4- 35000 5- 28000 6- 24000 7- 20000 Correspondence booked Journal is Hec W category,

🚨MRI in-bore biopsy following MRI/US fusion-guided biopsy ❓What is the value in patients with persistent suspicion of clinically significant prostate cancer 🖇️https://lnkd.in/dwBpZecm 🆃🅰️🅺🅴 🅷🅾️🅼🅴🆂 1️⃣ Systematic and targeted MRI/US fusion-guided biopsy can miss clinically significant prostate cancer. 2️⃣ MRI in-bore biopsy detected clinically significant prostate cancer in 47% after inconclusive MRI/US fusion-guided biopsy. 3️⃣ MRI in-bore biopsy can be used as a backup in case of discordant imaging and pathology. 🤝 congratulations to the authors @M. Quentin, @M. Boschheidgen, @J.P. Radtke, @F. Spohn, @T. Ullrich, @L. Drewes, @B. Valentin, @J. Lakes, @Al-Monajjed, @C. Arsov, @I. Esposito, @P. Albers, @G. Antoch, @L. Schimmöller, #ProstateCancer #MRIBiopsy #FusionGuidedBiopsy #CancerDetection #MedicalResearch

*Radiology paper* Gyne can also participate Effectiveness of Contrast-Enhanced Mammography in Breast Cancer Screening: A Randomized Controlled Trial" Available positions 1-8 1- 50000 2- 45000 3- 40000 4- 35000 5- 28000 6- 24000 7- 20000 8- 15000 Journal is Hec W category,

⚕️ Prostate MRI & PSMA PET For Precision Cancer Imaging PSMA PET and MRI form a hybrid approach offering precision in prostate cancer diagnosis and treatment planning, reducing unnecessary biopsies and improving outcomes. https://lnkd.in/ewA7PZ4b

Explore the recent Urology Times® Peer Exchange on the evolving role of biomarkers in prostate cancer. Watch Benjamin Lowentritt and a panel of experts discuss the utilization of biomarkers in prostate cancer treatment. Watch now: https://bit.ly/3XMswZY

Purysko and colleagues recently published a comprehensive literature review of the diagnostic accuracy of 68Ga-PSMA-11 PET/CT imaging in prostate cancer. The review, published in Applied Radiology, evaluated 76 publications in >5000 patients with prostate cancer who were imaged for primary staging or detection of biochemical recurrence. Results show that the majority of studies demonstrated a sensitivity ≥80% and a specificity ≥90% for detection of prostate cancer in both settings, and a sensitivity and specificity ranging up to 100% for detection in lymph nodes in both settings. This supports the robust real world evidence and clinical experience with 68Ga-PSMA-11 imaging and further demonstrates its efficacy and favourable safety profile. https://bit.ly/3Yh9wU4 Review article sponsored by Telix.

Explore the recent Urology Times® Peer Exchange on the evolving role of biomarkers in prostate cancer. Watch Benjamin H. Lowentritt, MD, FACS, and a panel of experts discuss the utilization of biomarkers in prostate cancer treatment. Watch now: https://bit.ly/3XMswZY